Mineralys Therapeutics Files Form 4
Ticker: MLYS · Form: 4 · Filed: Apr 14, 2026
Sentiment: neutral
Topics: insider-filing, ownership-change
TL;DR
Mineralys Therapeutics filed a Form 4 on 4/13/26 for ownership changes on 4/9/26.
AI Summary
On April 13, 2026, Mineralys Therapeutics, Inc. filed a Form 4, reporting changes in beneficial ownership of securities. The report covers transactions that occurred on April 9, 2026. Specific details regarding the nature of the transactions, the number of shares, and the individuals involved are not provided in this excerpt.
Why It Matters
Form 4 filings are crucial for investors as they disclose changes in stock ownership by company insiders, which can signal confidence or concerns about the company's future.
Risk Assessment
Risk Level: low — This filing is a standard disclosure of ownership changes and does not inherently indicate significant risk.
Key Players & Entities
- Mineralys Therapeutics, Inc. (company) — Issuer
- 0001933414 (company) — CIK for Mineralys Therapeutics, Inc.
- 0001672659-26-000020 (filing_id) — SEC Accession Number
- 2026-04-13 (date) — Filing Date
- 2026-04-09 (date) — Period of Report
FAQ
What specific changes in beneficial ownership were reported by Mineralys Therapeutics, Inc.?
The provided excerpt does not detail the specific changes in beneficial ownership, only that a Form 4 was filed to report them.
Who are the insiders involved in the reported ownership changes?
The excerpt does not name the specific individuals whose beneficial ownership changed.
What was the date of the transactions reported in the Form 4?
The period of report for the transactions was April 9, 2026.
When was the Form 4 filing accepted by the SEC?
The filing was accepted on April 13, 2026.
What is the CIK number for Mineralys Therapeutics, Inc.?
The CIK number for Mineralys Therapeutics, Inc. is 0001933414.
Filing Details
This Statement of Changes in Beneficial Ownership (Form 4) was filed with the SEC on April 14, 2026 regarding Mineralys Therapeutics, Inc. (MLYS). Form 4 filings disclose purchases, sales, or other changes in ownership by company insiders such as officers, directors, and major shareholders.